Skip to main content
. 2011 Sep 14;6(9):e24770. doi: 10.1371/journal.pone.0024770

Table 4. Phenotypic drug susceptibility profile and genetic sequence analysis of all cavities of each patient.

Patient Nos. Cavity Nos. (Lobe)a Phenotypic Drug Susceptibility profileb Genetic sequence analysis: mutation observed (codon number)c
Sensitive Resistant rpoB gene katG gene gyrA gene rrs gene
1 1 (LUL), 2 (LUL), 3 (LUL) PAS, Cfz S, H, R, E, Km, Eto, Ofx, Mfx, Am, Cm, Z C to T (531) G to C (315) A to G (94) A to G (1401)
2 1 (LUL) Cfz, Z S, H, R, E, K, Eto, PAS, Ofx, Mfx, Am, Cm C to T (531) G to C (315) A to G (94) A to G (1401)
2 (LUL) E, Km, Am, Cm, Z, Cfz S, H, R, Eto, PAS, Ofx, Mfx C to T (531) G to C (315) A to G (94) wtd
3 (LLL) E, PAS, Cfz S, H, R, K, Eto, Ofx, Mfx, Am, Cm, Z C to T (531) G to C (315) A to G (94) A to G (1401)
3 1 (LUL), 2 (LLL), 3 (LLL) S, Km, Am, Cfz, Cm H, R, E, Eto, PAS, Ofx, Mfx, Z C to T (531) G to C (315) A to G (94) Wt
4 1 (LUL), 2 (LUL), 3 (LUL) Cfz S, H, R, E, Km, Eto, PAS, Ofx, Mfx, Am, Cm, Z C to T (531) G to C (315) A to G (94) A to G (1401)
5 1 (RUL) Km, PAS, Am, Cfz, Cm S, H, R, E, Eto, Ofx, Mfx, Z C to T (531) G to C (315) A to G (94) wt
2 (RUL) Km, Am, Cfz, Cm S, H, R, E, Eto, PAS, Ofx, Mfx, Am, Z C to T (531) G to C (315) A to G (94) wt
3 (RLL) Km, Am, Cfz, Cm S, H, R, E, Eto, PAS, Ofx, Mfx, Am, Z C to T (531) G to C (315) A to G (94) wt
a

LUL, Left upper lobe; LLL, left lower lobe, RUL, right upper lobe; RLL, right lower lobe.

b

S: Streptomycin, H:Isoniazid, R:Rifampicin, E:Ethambutol, Km:Kanamycin, Eto:Ethionamide, PAS:para-aminosalicylic acid, Ofx:Ofloxocin, Mfx:Moxifloxacin, Am:Amikacin, Cfz:Clofaziamine, Cm:Capreomycin, Z:Pyrazinamide.

c

Cavity isolates showing variable drug susceptibility profiles were analyzed by in-house RLBH (except for Ethambutol, PAS, Pyrazinamide, wherein phenotypic DST were repeated to confirm the variable drug susceptibility profile).

d

wt – wild type.